A real-world study reported that Nefecon, the targeted-release formulation of budesonide, reduced proteinuria and helped preserve kidney function in patients with primary IgA nephropathy, including those starting with relatively low levels of protein leakage. The findings add practical evidence to the existing clinical development record. The study’s emphasis on “real-world” populations is notable for IgA nephropathy, where baseline risk and care pathways can differ from strict trial inclusion criteria. If replicated, the results could support broader use decisions for clinicians seeking kidney-protective effects without restricting eligibility to high-proteinuria cohorts. For payers and guideline developers, real-world kidney outcomes—particularly around proteinuria as a surrogate for long-term risk—are central to assessing value. The report also reinforces the role of targeted steroids as a non-immunosuppressive-chemistry alternative within established standards. (Story coverage source: real-world evidence report.)